JHU-083 is primarily investigated for its potential therapeutic applications in the field of oncology. It functions as a glutamine antagonist, targeting the metabolic pathways that cancer cells rely on for growth and survival. By inhibiting glutamine metabolism, JHU-083 disrupts the ability of cancer cells to proliferate, making it a promising candidate for cancer treatment. Research has shown its efficacy in preclinical models, particularly in cancers that are highly dependent on glutamine, such as certain types of leukemia and solid tumors. Additionally, JHU-083 is being explored for its potential to enhance the effectiveness of other cancer therapies, including chemotherapy and immunotherapy, by sensitizing cancer cells to these treatments. Its application is also being studied in the context of modulating the tumor microenvironment, potentially reducing immune suppression and improving anti-tumor immune responses.